← All trials
NCT05586074
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2022
- Primary completion
- Feb 10, 2026
- Completion date
- May 14, 2026
- First posted
- Oct 19, 2022
- Last posted
- Oct 19, 2022
- Enrollment
- 324
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sunshine Lake Pharma Co., Ltd.Lead sponsor
- Zhejiang UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.